Novartis Reports Results of QMF149 in P-III PALLADIUM Study for Patients with Uncontrolled Asthma

Shots:

• The P-III PALLADIUM study involves assessing of QMF149 [indacaterol acetate + mometasone furoate (IND/MF)] vs mometasone furoate (MF) as monothx. in 2,216 asthma patients with medium or high dose ICS or low dose ICS/LABA use 3mos. prior to screening, a pre-bronchodilator FEV1 of ≥50%, >80% of the predicted normal value for the patient and an ACQ-7 score >1.5
• The P-III PALLADIUM study resulted in meeting its 1EPs & 2EPs i.e, improvement in FEV1 @26wks.; improvement in Asthma ACQ-7 @26wks., improvement in peak expiratory flow, exacerbation rates, rescue medication. Additionally, QMF149 showed improvement in lung function when compared with LABA/ICS
• QMF149 (qd) is an investigational inhaled combination therapy of IND (a LABA [long-acting beta agonist]) and glycopyrronium bromide (a LAMA [long-acting muscarinic receptor antagonist]) with an anti-inflammatory action of MF (high- or medium-dose ICS [inhaled corticosteroid]), delivered via Breezhaler device

Click here to­ read full press release/ article | Ref: Novartis | Image: Wall Street Journal